SEC filings

Water Tower Research’s new research report takes a close look at how eXoZymes is moving from a promising scientific platform toward a potentially scalable commercial business. 

The report identifies NCT as the company’s most important near-term opportunity and highlights the dramatic progress made in taking it from laboratory development toward commercial production. It also explores the much larger opportunity behind the platform - including potential pharmaceutical applications, cannabinoids, santalene and a pipeline of new molecules - while outlining the milestones that could determine how quickly eXoZymes can turn its technology into partnerships, products and revenue. 


7 things to know from the report:

eXoZymes announced that it scheduled its 2026 annual meeting of shareholders for November 13, 2026, setting a formal timeline for its upcoming governance and voting activities. The company established September 15, 2026 as the record date to determine eligible shareholders and indicated plans to distribute proxy materials around September 28, 2026, clarifying key deadlines for investor participation.